Med Spa Profit Margins: What Is Published, What Is Not, and What You Have to Compute Yourself

No federal statistical product publishes a profit figure for the industries that contain med spas, read on 19 August 2026. The 2022 Economic Census has an operating-expenses field, and for taxable establishments in both candidate NAICS codes it is flagged "N", meaning the Bureau did not publish it. County Business Patterns carries establishments, employment and payroll, and no receipts field at all.

So the margin numbers that circulate in this industry come from somewhere else. Usually a manufacturer's quarterly revenue line, read as if it were a demand signal, or a paid survey whose public page states no reference year and no sample size.

The received wisdom is that AbbVie's aesthetics results tell you what is happening to procedure volume, and therefore to your prices. AbbVie's own filing says otherwise. Its FY2025 Form 10-K names the causes of the US Botox Cosmetic decline in a specific order, and consumer demand is third on the list.

This post reads the actual filings, inventories every genuinely public source of med spa economics with what each one will and will not give you, then builds the one margin number that is yours to compute: margin per treatment hour.

Every source on this page was read on 19 August 2026. We make med spa software, so we have an obvious interest in you tracking price, product cost and chair time inside a system rather than in a spreadsheet. The arithmetic and the source record below hold regardless of whose software you run them in.

What AbbVie's FY2025 filing actually reports

AbbVie's Form 10-K for the fiscal year ended 31 December 2025, filed 20 February 2026, carries a product revenue table in Management's Discussion and Analysis that splits every aesthetics line into United States and International.

US Juvederm Collection net revenues were $385 million in 2025 against $469 million in 2024, a change of 18.0%. US Botox Cosmetic net revenues were $1,504 million against $1,682 million, a change of 10.5%. Both figures repeat exactly in the Key Product Revenues table of AbbVie's full-year results press release dated 4 February 2026.

One detail changes how you may quote these. The product table appears twice in the 10-K. The version inside the audited financial statements, the revenue disaggregation note, carries dollars only. The percentages appear in MD&A and in the earnings release, neither of which is covered by the audit opinion. The dollar amounts are audited; the percentage changes are unaudited computations from those audited dollars.

Scale matters too. Inside AbbVie's $2,990 million of US aesthetics revenue for 2025, Botox Cosmetic was $1,504 million, Other Aesthetics $1,101 million and Juvederm Collection $385 million. The Juvederm line quoted as an industry bellwether is 12.9% of AbbVie's own US aesthetics revenue.

The filing puts price first and demand third

The driver sentence in the FY2025 10-K reads: "In the United States, Botox Cosmetic net revenues decreased 11% primarily driven by unfavorable pricing due to customer loyalty program changes, lower market share and decreased consumer demand, partially offset by the timing of customer inventory destocking in the prior year."

The 11% in that sentence is an MD&A narrative figure, and AbbVie's narrative percentages are stated on a constant-currency basis. The table's US Botox Cosmetic line reads 10.5%, and for a US column reported and constant currency are the same by construction. Pricing from loyalty-program changes is named first, market share second, consumer demand third, with a channel-inventory timing effect working the other way. That single line is a composite of four forces and the filing does not weight them.

The Juvederm attribution is narrower still. AbbVie writes that "Net revenues for Juvederm Collection decreased 15% in 2025 primarily driven by decreased consumer demand, partially offset by the timing of customer inventory destocking in the prior year." That sentence is global, and its 15% is a constant-currency narrative figure: the table gives 15.6% reported and 15.3% operational for global Juvederm, against 18.0% for the US line. AbbVie publishes no separate driver sentence for the US figure, read on 19 August 2026.

The consequence is blunt. If you reprice a filler menu because a manufacturer's US revenue line moved, you are pricing off a number that blends list price changes, loyalty-program mechanics, share shifts between brands, wholesaler stocking decisions and consumer behaviour, with no way to separate them from outside the company.

Three traps in every aesthetics headline

The first trap is basis. AbbVie's tables print both reported and operational (constant-currency) percentages. Its narrative prints operational only, and the two differ. The FY2025 narrative says Juvederm "decreased 15%" while the table gives 15.6% reported and 15.3% operational for the global line. The Q2 2026 10-Q narrative says Botox Cosmetic "increased 3% for the three months and 10% for the six months" while the global table line gives 5.2% and 11.9% reported, 3.4% and 9.5% operational. Quote the sentence rather than the table and you have silently published a constant-currency figure.

The second trap is audit status. Every AbbVie Key Product Revenues table is headed "(Unaudited)". The Evolus 10-Q financial statements are headed "(unaudited)". Only annual financial statements carry an audit opinion, and even inside the 10-K the product percentages sit in MD&A, outside it.

The third trap is the US column. US reported change equals US operational change by construction, because US revenue is already denominated in dollars. That is why the US Juvederm line shows 18.0% in both columns while the global line shows 15.6% and 15.3%. Nothing about the US market caused that gap. Currency did.

The 2026 filings reverse the 2025 story

Here are AbbVie's US aesthetics lines across the last three reported periods, from the Key Product Revenues tables in the 4 February 2026 full-year results press release, the SEC-filed Form 8-K exhibit of 29 April 2026 and the 31 July 2026 second-quarter results press release. All figures are US net revenues in millions of dollars, reported basis.

The same product, in the same market, moved from down 18.0% over twelve months to up 12.2% in a quarter to down 2.0% in the next, netting up 3.9% across the half. US Botox Cosmetic ran down 10.5%, then up 25.8%, then down 2.4%, netting up 9.4%.

Distrust the rebound as much as the decline. The Q1 2026 comparison is against a Q1 2025 US quarter that the FY2025 filing attributes partly to loyalty-program pricing changes, and a weak base produces a large percentage without a single extra syringe moving.

Two consequences follow. Any pricing decision anchored on a single annual manufacturer percentage would have been reversed twice within eight months. And the size of the swing is the argument: a line that moves from up 25.8% to down 2.4% on the same product in consecutive quarters is not measuring how many people booked.

Sell-in is not sit-in

AbbVie's 10-K states that substantially all of its US pharmaceutical product net revenues are to three wholesalers. The number records shipments into a channel, net of rebates, not treatments performed in clinics. Between AbbVie's invoice and your syringe sit wholesaler stocking decisions, practice buying patterns and rebate programs that settle later.

Evolus makes the accounting side concrete. Its Form 10-Q for the quarter ended 30 June 2026, filed 5 August 2026, states that "Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume-based rebates, consumer loyalty programs and co-branded marketing programs," and that for loyalty customers "the invoice price is allocated between the product sold and the material right associated with the reward."

That has a direct implication for your menu. Manufacturer net revenue is already stated after consumer loyalty discounting. When you run your own promotion on top of a product bought under a loyalty program, you are applying a second discount to an input whose reported price already absorbed the first. Model both layers together. Our note on med spa membership program pricing works through the same stacking problem on the recurring-revenue side.

What the challengers disclose, and what they leave out

Evolus reports product-level revenue in the segment note of its 10-Q. For the three months ended 30 June 2026: Jeuveau $74,456 thousand against $58,968 thousand a year earlier, and Evolysse $8,894 thousand against $9,731 thousand. Total net revenues were $84,084 thousand against $69,387 thousand, up 21.2%, with cost of goods sold of $26,904 thousand and gross profit of $57,180 thousand.

Note the second line: Evolysse revenue in the filed segment note is lower than the same quarter a year earlier. The MD&A explains the total only as "primarily due to higher Jeuveau sales." Evolus publishes no unit count, no average selling price and no volume-versus-price bridge in that filing, read on 19 August 2026.

Galderma is the counterweight. Its press release of 23 July 2026, published by the company and therefore an interested source rather than a filed financial statement, reports first-half 2026 worldwide Injectable Aesthetics net sales of 1,437 million USD against 1,240 million, up 12.1% at constant currency and 15.9% reported. Neuromodulators were 826 million USD, up 13.4% at constant currency; Fillers & Biostimulators 611 million USD, up 10.5% at constant currency. Galderma's volume attribution in that release is attached to total company net sales growth of 24.6% at constant currency, a figure spanning therapeutic dermatology and skincare as well as injectables.

Revance filed Form 15-12G on 18 February 2025, certifying one holder of record under Rules 12g-4(a)(1) and 12h-3(b)(1)(i). Revance publishes no financial statements for any period after 2024, read on 19 August 2026.

One manufacturer's US lines fell across 2025 while a competitor's worldwide injectables category grew at double digits in the first half of 2026. The periods do not line up, and neither figure is a procedure count. What the pair is consistent with is share moving between brands. It is not evidence about how many faces were injected.

The one published product price

Allergan Aesthetics publishes a wholesale acquisition cost disclosure for Botox Cosmetic under Connecticut Public Act No. 23-171, document reference BCT-v2.0, current as of February 2024. The table lists NDCs: the 100-unit vial, NDC 00023-9232-01, at $656.00 per vial, and the 50-unit vial, NDC 00023-3919-50, at $362.00 per vial. That is $6.56 per toxin unit on the 100-unit vial and $7.24 per unit on the 50-unit vial.

Two caveats travel with it. The document states that "Wholesale Acquisition Cost (WAC), also known as list price, is established by AbbVie. WAC may not reflect the price paid by patients or insurers." And Allergan Aesthetics publishes no version of that disclosure newer than February 2024 on its site, read on 19 August 2026, which makes the figure roughly two and a half years old. It is a reference point, not your invoice.

For comparison, the Centers for Medicare & Medicaid Services July 2026 Part B Payment Limit File, dated 16 June 2026, lists J0585 onabotulinumtoxinA at $6.506 per unit and J0588 incobotulinumtoxinA at $5.285 per unit. Those are payment limits set at 106% of average sales price under 42 CFR 414.904(a)(2), for therapeutic products billed to Medicare. Botox Cosmetic is a separate product that is not billed to Medicare.

Fillers are different. Allergan Aesthetics' disclosure index lists wholesale acquisition cost for three products, all of them drugs. Allergan Aesthetics publishes no price for Juvederm or any hyaluronic acid filler on that index, read on 19 August 2026, and the CMS payment limit file carries no HCPCS code for any HA filler. Juvederm is a premarket-approval medical device rather than a drug, so drug price transparency statutes do not reach it. Filler cost arithmetic has to run on your own invoice.

What is genuinely public about med spa economics

The table below is the inventory of sources we retrieved on 19 August 2026, what each publishes without payment, and the specific thing each one does not publish.

Read the two Economic Census rows against each other. Receipts per establishment work out to $460,633 for NAICS 812199 and $1,883,116 for taxable NAICS 621498. That is a fourfold gap driven by which code a business sits in rather than by anything a med spa does differently. Both codes are mixed bags. Neither is a med spa code.

The lag is worth naming precisely rather than as a blanket claim. Economic Census 2022 receipts reached the public in December 2024, County Business Patterns 2023 in June 2025, OEWS May 2025 in May 2026. Modeled products such as IBISWorld carry no lag, because they are estimates rather than counts.

What you can benchmark from this record is payroll intensity, not profit. Payroll was 35.5% of receipts across all NAICS 812199 establishments in 2022. That is a ratio you can compute on your own books this afternoon.

What BLS publishes about injector pay

The Occupational Employment and Wage Statistics program, news release USDL-26-0725, released 15 May 2026 for the May 2025 reference period, gives national annual figures: Nurse Practitioners (29-1171) at a $137,300 mean and $132,300 median, Physician Assistants (29-1071) at $141,280 mean, Registered Nurses (29-1141) at $101,420 mean, and Skincare Specialists (39-5094) at a $51,850 mean and $45,330 median.

One common caveat about these figures is wrong in a way that matters. OEWS technical notes state that the wage includes "incentive pay, including commissions and production bonuses." The published means already absorb commission. The real coverage hole is different, and the notes are explicit: "The survey does not include the self-employed, owners and partners in unincorporated firms." Owner-injectors are absent from every cell.

At the industry level, the nearest published cells are four-digit. In NAICS 812100 Personal Care Services, Nurse Practitioner employment is 1,620 with an hourly mean of $60.57; Skincare Specialists number 53,350 at a $24.20 hourly mean. In NAICS 621400 Outpatient Care Centers, Nurse Practitioner employment is 31,590 with an hourly mean of $71.58. NAICS 812100 also contains hair, nail and barber shops, so it is not a clean med spa read.

The $11.01 hourly gap between those two cells is the usable output. It is a defensible range for what an employed injector hour costs before benefits, and it is the input the next section needs.

Gross margin is the wrong subtraction

Gross margin subtracts product cost and stops. AbbVie's audited FY2025 statements of earnings show net revenues of $61,160 million and cost of products sold of $18,204 million; MD&A presents the resulting gross margin of $42,956 million, 70% of net revenues. A clinic hour is not like that. The costs that decide whether the hour was worth running are the product consumed, the provider's pay for that hour, and the discount granted at the counter. Only the first is inside gross margin.

On the status of the alternative: Regulation S-X, 17 CFR 210.5-03, prescribes the captions "Net sales of tangible products (gross sales less discounts, returns and allowances)" and "cost of tangible goods sold." It contains no contribution-margin caption. Our own editorial check on 19 August 2026 retrieved no definition of contribution margin published by an accounting standard setter or professional body from a primary source, which is a statement about what we could retrieve rather than proof that no definition exists. Treat it as a management measure you define and document yourself.

What is verifiable is how such a measure is classified. Regulation G, 17 CFR 244.101(a)(2), states that a non-GAAP financial measure "does not include operating and other financial measures and ratios or statistical measures calculated using exclusively one or both of: (i) Financial measures calculated in accordance with GAAP; and (ii) Operating measures or other measures that are not non-GAAP financial measures." A margin built from booked revenue and recorded cost, divided by treatment hours, sits inside that carve-out. The rule binds SEC registrants rather than private clinics, but it is the cleanest available description of what the metric is made of.

Margin per treatment hour, built parametrically

Four inputs, all of which exist in your own records: chair time booked, gross price charged, discount actually granted, and product consumed at your invoice cost. Then one external input for provider cost, which BLS supplies. The table below runs a toxin hour against a filler hour. Every dollar figure marked placeholder is illustrative and should be replaced with your own.

The first thing the table shows is that the hour with the larger ticket is not the better hour. At these placeholders the toxin hour bills $210 more and finishes $11 behind, because product is a much larger share of the toxin ticket. That ordering flips as soon as you change any one input, which is why the calculation has to run on your invoices rather than on someone else's benchmark.

The second is what a routine discount costs. A ten percent price cut removes $96 from the toxin hour, 20.9% of the $459.43 the hour would otherwise have produced. On the filler hour the same ten percent removes 16.7%. The higher the product share of the ticket, the more of the margin a percentage discount takes.

The third is that provider cost is the smallest of the three subtractions and the one owners spend the most time on. Swapping the NAICS 812100 hourly mean of $60.57 for the NAICS 621400 mean of $71.58 costs $11.01 per hour, about 3% of the toxin hour's margin. The discount line is nearly nine times more powerful than the wage line at these values.

The model leaves out rent, front desk, marketing and equipment. Adding them turns this into a full profit figure, a harder calculation. Per-hour margin is useful precisely because it isolates the three things a single booking decision controls.

What your software has to do for this to be measurable

This is a requirements list, not a product review. To compute margin per treatment hour without a manual reconciliation every month, your system needs five things.

It has to record scheduled and actual duration separately, because the arithmetic above changes when a booked hour runs seventy minutes. It has to store gross price and discount as separate fields on the line item, since a net-only record makes the 20.9% calculation impossible after the fact. It has to attach product consumption to the treatment line, in units for toxin and by product identifier for filler. It has to hold your invoice cost per unit with an effective date, because a mid-quarter price change otherwise rewrites your history. And it has to attribute the line to a provider, so the wage input is the right one.

If any one of the five is missing, the number you produce will be a monthly average that hides exactly the variation you are trying to see. Related reading on the retention side of the same arithmetic: retention versus acquisition economics, and the mechanics of running rewards without stacking discounts blindly in loyalty software. To see the fields above in a live system, book a demo.

Run these four numbers before the next quarter closes

First, compute payroll as a percentage of receipts for your last full year. The comparison point is 35.5%, which is what NAICS 812199 showed across 29,692 establishments in the 2022 Economic Census. It is a mixed-bag code, so treat it as a rough boundary rather than a target.

Second, pull every discounted line from your last ninety days, sum the discount granted, and divide by the margin those lines would have produced at full price. If that ratio is above 20%, your discounting is doing more to your margin than any wage decision you are likely to make this year.

Third, compute margin per treatment hour separately for toxin and for filler, using the structure above and your own invoice costs. Run it monthly and keep the series. A single quarter tells you nothing; four quarters tell you which service line is carrying the schedule.

Fourth, when a manufacturer's quarterly number is quoted at you, check three things before it changes any price on your menu: whether the figure is reported or constant currency, whether it is the US column or the global one, and what the prior-year quarter looked like. Applying that check to the AbbVie table above would have stopped two price changes in eight months.

Frequently asked questions

What is the average profit margin for a med spa?

No federal statistical product publishes a profit margin figure for med spas, read on 19 August 2026. The 2022 Economic Census carries an operating-expenses field flagged "N" for taxable establishments in both NAICS 812199 and 621498, and no net income or owner compensation field at all. County Business Patterns 2023 publishes establishments, employment and payroll with no receipts field. IBISWorld's Health & Wellness Spas report places profit behind its paywall.

Did US Botox Cosmetic revenue really fall 10.5% in 2025?

Yes. AbbVie's Form 10-K for the year ended 31 December 2025 reports US Botox Cosmetic net revenues of $1,504 million against $1,682 million, a change of 10.5%, and the same figure appears in the Key Product Revenues table of the 4 February 2026 results press release. The dollar amounts are audited. The percentage itself is an unaudited computation presented in Management's Discussion and Analysis.

Does a manufacturer's revenue decline mean fewer people are getting treated?

Not on its own. AbbVie's 10-K states that substantially all of its US pharmaceutical net revenues are to three wholesalers, so the line measures shipments into a channel net of rebates. Its own driver sentence for US Botox Cosmetic names unfavorable pricing from loyalty program changes first, lower market share second, and decreased consumer demand third, with inventory destocking timing working the other way.

How much does Botox Cosmetic cost per unit?

Allergan Aesthetics publishes a wholesale acquisition cost under Connecticut Public Act No. 23-171, document BCT-v2.0, current as of February 2024: $656.00 for the 100-unit vial and $362.00 for the 50-unit vial, which is $6.56 and $7.24 per toxin unit respectively. The document states that WAC may not reflect the price paid by patients or insurers, and it is a list price rather than what a clinic is invoiced.

Is there a published price for Juvederm or other fillers?

Allergan Aesthetics publishes no price for Juvederm or any hyaluronic acid filler on its disclosure index, read on 19 August 2026. That index lists wholesale acquisition cost for three products, all of them drugs, and the CMS Part B payment limit file carries no HCPCS code for HA fillers. Juvederm is a premarket-approval medical device rather than a drug, which is why drug price transparency statutes do not reach it.

What do injectors actually earn?

The BLS Occupational Employment and Wage Statistics program, May 2025 reference period released 15 May 2026, reports a national annual mean of $137,300 for Nurse Practitioners and $141,280 for Physician Assistants. In NAICS 812100 Personal Care Services the Nurse Practitioner hourly mean is $60.57; in NAICS 621400 Outpatient Care Centers it is $71.58. These figures already include commissions and production bonuses, and they exclude self-employed people and owners of unincorporated firms.

Is contribution margin a GAAP measure?

Our own editorial check on 19 August 2026 retrieved no definition of contribution margin published by an accounting standard setter or professional body from a primary source, which is a statement about what we could retrieve rather than proof that no definition exists. Regulation S-X at 17 CFR 210.5-03 prescribes captions for net sales of tangible products and cost of tangible goods sold, and contains no contribution-margin caption. Treat it as a management measure you define and document yourself, and write the definition down so the number is reproducible next quarter.